Danish newcomer comes up trumps in psoriasis

22 August 2018

A privately-held Danish company that is developing topical therapies for skin and eye diseases has announced positive Phase III data on its MC2-01 Cream (calcipotriene and betamethasone dipropionate).

MC2 Therapeutics is confident that its topical drug vehicle called PAD improves the delivery, efficacy and patient experience of existing active pharmaceutical ingredients that are only available in suboptimal dosage forms.

The Phase III trial comparing MC2-01 to LEO Pharma’s Taclonex (calcipotriene and betamethasone dipropionate) topical suspension showed statistically-significant superiority in both treatment success and patient reported treatment convenience for the MC2 cream.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK